

MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital-263 001, Uttarakhand,

W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com, Tel: 9871862796

MPL/33/QTR-3/2019-20

13th February, 2020

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

Scrip ID: MESPHAR-B

Scrip Code: 500274

Sub: Un-Audited Financial Results for the Quarter ended 31st December, 2019

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Un-Audited Financial Results for the Quarter and nine months ended 31st December, 2019.

M/s. Sangram Paul & Co., Chartered Accountants, Statutory Auditors of the Company has issued the Limited Review Report

The Board meeting commenced at 01:30 P.M. and concluded at ~~02:00~~ 03:00 PM

A Copy of the said results together with Limited Review Report is enclosed herewith. These results are also being made available on the website of the Company at <http://www.mescopharma.com/>


This is for your information and records.

Thanking You,

Yours Faithfully,

For Meseo Pharmaceuticals Limited

For Meseo Pharmaceuticals Limited



Nurani Shankar Parameswaran
Company Secretary cum Compliance Officer

Sangram Paul & Co.

S.K. Paul. F.C.A
Chartered Accountant

Chartered Accountants
Plot No.-754/15, Jayadev Vihar, Bhubaneswar-751 013
Phone : 0674-2360863, Mob. : 9337116878

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

**To the Board of Directors of
Mesco Pharmaceutical Limited**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **MESCO PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and nine months ended 31st December, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sangram Paul & Co.
Chartered Accountants
Firm Registration No. 308001E
UDIN: 20013015AAAAAD3002

S.K. Paul
S.K. Paul
Proprietor
M. No.: - 013015
Date: 13th February, 2020



MESCO PHARMACEUTICALS LTD

CIN : L24111UR1986PLC015895

REGD.OFFICE : UPPER KESALTON, TALLITAL, NAINITAL-263 001, UTTARAKHAND

Tel. :011-41587085, E-mail : nsparameswaran@mescosteel.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2019

(In Rs.)

S. No.	PARTICULARS	Quarter Ended			9 Months Ended		Year Ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		UNAUDITED	AUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Income from Operations						
	(a) Net Sales/ Income from operations	-	-	-	-	-	-
	(b) Other Income	-	-	-	-	-	-
	Total Income from Operations (net)	-	-	-	-	-	-
2	Expenses						
	(a) Cost of Material Consumed	-	-	-	-	-	-
	(b) Change in Inventories of finished goods and work in progress	-	-	-	-	-	-
	(c) Employees Benefits Expenses	-	-	-	-	-	-
	(d) Depreciation and Amortisation expenses	-	-	-	-	-	-
	(e) Finance Cost	-	-	-	-	-	-
	(f) Other Expenses	11,942.82	110,728.00	45,728.00	122,670.82	3,916,680.00	4,098,032.83
	Total Expenses	11,942.82	110,728.00	45,728.00	122,670.82	3,916,680.00	4,098,032.83
3	Profit/(Loss) Before Exceptional items and Tax Finance Costs & Exceptional Items (1-2)	(11,942.82)	(110,728.00)	(45,728.00)	(122,670.82)	(3,916,680.00)	(4,098,032.83)
	Exceptional Items	-	-	-	-	-	-
4	Profit/(Loss) before Tax	(11,942.82)	(110,728.00)	(45,728.00)	(122,670.82)	(3,916,680.00)	(4,098,032.83)
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax	-	-	-	-	-	-
	(c) Tax expense relating to Earlier years	-	-	-	-	-	-
7	Profit for the Period	(11,942.82)	(110,728.00)	(45,728.00)	(122,670.82)	(3,916,680.00)	(4,098,032.83)
	Other Comprehensive Income						
	If any	-	-	-	-	-	-
	Total Comprehensive Income for the Period	(11,942.82)	(110,728.00)	(45,728.00)	(122,670.82)	(3,916,680.00)	(4,098,032.83)
14	Paid up Equity Share Capital	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00	197,381,000.00
	(Face value Rs. 10/- per Equity Share)						
16	Earning per share (before and after extraordinary items)						
	(Rs.10- each)						
	Basic (Rs.)	(0.00)	(0.01)	(0.00)	(0.06)	(1.93)	(0.20)
	Diluted (Rs.)	(0.00)	(0.01)	(0.00)	(0.06)	(1.93)	(0.20)

Notes :


- The above Results, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective Board Meeting held on 13th February, 2020
- The Statutory Auditors of the Company have carried out Limited Review of the above Results.
- Figures for the previous period have been re-classified, re-grouped/ re-arranged wherever
- There were no manufacturing activities in the company during the period under consideration
- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder

Date: 13.02.2020

Place: New Delhi

FOR AND ON BEHALF OF THE BOARD

For Mesco Pharmaceuticals Limited



Managing Director

DIN: 06862254